BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novozymes Biopharma to Present Latest Advances in Cell Culture Technology at ESACT


4/12/2011 10:48:31 AM

NOTTINGHAM, UK - April 12, 2011 - Novozymes Biopharma, part of Novozymes A/S, world leader in bioinnovation, today announced that the company will present two scientific posters at the 2011 ESACT meeting, May 15-18, Vienna, Austria. The posters highlight the application of animal-free recombinant supplements in cell-based viral vaccine production as well as animal-free cryopreservation and recovery media. For more information or to request a copy of the scientific posters, please visit booth #117 at the 2011 ESACT meeting or www.biopharma.novozymes.com.

"Novozymes is delighted to present its latest study findings in cell culture applications at ESACT," comments Dermot Pearson, Marketing Director at Novozymes Biopharma. "We're working continuously to develop solutions for the industry's most challenging problems and are pleased to be able to demonstrate these latest advances that will help to optimize each stage of the biomanufacturing process."

The first new poster, entitled "Application of animal-free recombinant bioactive protein supplements to improve the performance of cell-based viral vaccine production," demonstrates the potential of protein supplements to improve growth performance of cell culture media in the absence of serum for cell types important in viral vaccine production.

The second poster, entitled "Animal-free cryopreservation and recovery media," examines recombinant human albumin (rAlbumin) for its ability to replace serum in the cryopreservation of CHO and hybridoma (Sp2/0) cells. Recombinant forms of other protein components of serum are also assessed for their ability to support cell growth during the initial recovery period following thawing. The findings of both studies will be presented at ESACT 2011.

During the meeting, Dr. Nicholas Timmins, Research Fellow, Australian Institute of Bioengineering and Nanotechnology, The University of Queensland, will deliver a presentation entitled "Ultra High Yield Manufacture of Red Blood Cells (RBC) in Fully Defined Animal Component Free Medium." The presentation will demonstrate how using Novozymes' recombinant transferrin and albumin products can eliminate the use of animal- and donor-derived medium components in RBC production. The presentation will take place on May 16 during Session II: Cells as Therapies and Stem Cells.

For further information on Novozymes' range of cell culture products or to request a copy of the scientific posters, please visit booth #117 at the 2011 ESACT meeting or www.biopharma.novozymes.com.

About Novozymes

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace. Read more at www.novozymes.com.

Contact:

Novozymes Biopharma: Sally Vernon, Customer Communications Manager SYKE@novozymes.com Tel. +44 115 955 3355

MEDIA CONTACTS

Europe

René Tronborg

Office: +45 4446 2274

Mobile: +45 3077 2274

retr@novozymes.com

US

Paige Donnelly

Office: +1 919 494 3209

Mobile: +1 919 218 4501

pagd@novozymes.com

China

Zhu Xiaoqing

Office: +86 106 298 7888+362

Mobile: +86 138 012 40590

xqzh@novozymes.com

Brazil

Saionara Ribeiro de Paula

Office: +55 41 3641 1112

Mobile: +55 41 9971 7225

saio@novozymes.com

INVESTOR CONTACTS

Europe

Tobias Bjorklund

Office: +45 4446 8682

Mobile: +45 3077 8682

tobb@novozymes.com

US

Thomas Steenbech Bomhoff

Mobile: +1 919 649 2565

tsbm@novozymes.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES